NeuroOne Medical Technologies Corporation will participate in the Oppenheimer 36th Annual Healthcare MedTech & Services Conference virtually on March 17, 2026. President and CEO Dave Rosa and CFO Ron McClurg will host one-on-one meetings with institutional investors, with Rosa scheduled to deliver a company presentation at 1:20 p.m. Eastern Time.
The presentation will focus on commercialization updates and pipeline milestones for the OneRF platform, which is designed for treatment of the brain, pain management, and advanced drug delivery. This conference appearance matters because NeuroOne's technologies directly address significant healthcare challenges in neurological disorder treatment, potentially transforming how conditions are diagnosed and managed surgically.
NeuroOne's medical technology platform includes four FDA-cleared product families: Evo Cortical Electrodes, Evo sEEG Electrodes, OneRF Ablation System for brain treatment, and OneRF Trigeminal Nerve Ablation System. These minimally invasive, high-definition electrode technologies offer combination diagnostic and therapeutic functions that could reduce hospitalizations, lower healthcare costs, and improve patient outcomes. The company's research and development extends to drug delivery and spinal cord stimulation programs, indicating broader applications for neurological care.
The importance of NeuroOne's participation in this conference extends beyond investor relations. The company's technologies represent potential advancements in treating neurological disorders that affect millions worldwide. By offering minimally invasive options with both diagnostic and therapeutic capabilities, NeuroOne's approach could reduce the need for multiple surgical procedures and hospital stays, addressing both patient burden and healthcare system costs. The OneRF platform specifically targets brain conditions, pain management, and drug delivery challenges that have historically required more invasive approaches with longer recovery times.
For the medical technology industry, NeuroOne's progress with the OneRF platform demonstrates continued innovation in neurological care. The company's FDA-cleared products already provide alternatives to traditional surgical approaches, and their ongoing research into drug delivery and spinal cord stimulation suggests further expansion of treatment options. The virtual presentation at the Oppenheimer conference will be accessible through the webcast link, with additional conference information available at the conference website.
NeuroOne's technologies operate under federal restrictions requiring physician oversight, emphasizing their specialized medical application. The company's focus on improving surgical care options for neurological disorder patients addresses a critical healthcare need, as neurological conditions often require complex, multi-procedure treatment pathways. By potentially consolidating diagnostic and therapeutic functions into fewer procedures, NeuroOne's platform could streamline patient care while maintaining treatment efficacy.
